Moderna Shares Fall for Seventh Consecutive Session Amid Bearish Analyst Sentiment

Moderna (MRNA) shares experienced their seventh straight session of declines on Wednesday, marking the company's longest losing streak since November 2024. This downward trend follows a significant year-to-date rally of nearly 600%, which has prompted analysts to adopt more cautious and bearish outlooks regarding the stock's valuation. The market reaction reflects growing skepticism among investors following the massive price surge earlier in the year. As analysts issue new warnings, the stock continues to face selling pressure as it seeks a new equilibrium after its rapid ascent.

3 articles from 1 source · updated

Coverage